Evidence map›Paper›PMID 35552983›Full record

ReviewPharmaceutical research2022

Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications.

Raj Kumar, Piyush Mehta, Konathala Ravi Shankar, Manju A K Rajora, Yogendra Kumar Mishra, Ebrahim Mostafavi, Ajeet Kaushik

Erratum issuedOpen access · hybridAbstract readReview
In one paragraph

Review in Pharmaceutical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. RSC advances · 2025
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 3 countries.

Raj KumarDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68105, USA. rk7410@gmail.com.ORCID http://orcid.org/0000-0002-5497-9678
Piyush MehtaPharmaceutical Technology Center, Department of Aerosol, Zydus Life Sciences Ltd., Ahmedabad, Gujarat, India.
Konathala Ravi ShankarSchool of NanoSciences, Central University of Gujarat, Gurajat, India.
Manju A K RajoraCollege of Nursing, All India Institute of Medical Sciences, New Delhi, 100029, India.
Yogendra Kumar MishraMads Clausen Institute, NanoSYD, University of Southern Denmark, Alsion 2, 6400, Sønderborg, Denmark.
Ebrahim MostafaviStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Ajeet KaushikSchool of Engineering, University of Petroleum and Energy Studies (UPES), Dehradun, Uttarakhand, India.
All India Institute of Medical Sciences · INCadila Healthcare (India) · INCardiovascular Institute of the South · USCentral University of Gujarat · INFlorida Polytechnic University · USNebraska Medical Center · USUniversity of Southern Denmark · DK

Funding

Multi-Disciplinary Training Program in Cardiovascular Imaging at StanfordT32EB009035 · NIBIB · STANFORD UNIVERSITY · PI Koen Nieman, John M. Pauly · 2008 to 2026
$4.3M
NIBIB NIH HHS T32 EB009035
6 · The paper itself

Abstract

purposeRespiratory disorders pose a major threat to the morbidity and mortality to public health. Here we reviewed the nanotechnology based pulmonary drug delivery using metered dose inhalers.

methodsMajor respiratory diseases such as chronic obstructive pulmonary diseases (COPD), asthma, acute lower respiratory tract infections, tuberculosis (TB) and lung cancer. At present, common treatments for respiratory disorders include surgery, radiation, immunotherapy, and chemotherapy or a combination. The major challenge is development of systemic delivery of the chemotherapeutic agents to the respiratory system. Conventional delivery of chemotherapy has various limitation and adverse side effected. Hence, targeted, and systemic delivery need to be developed. Towards this direction nanotechnology, based controlled, targeted, and systemic drug delivery systems are potential candidate to enhance therapeutic efficacy with minimum side effect. Among different route of administration, pulmonary delivery has unique benefits such as circumvents first pass hepatic metabolism and reduces dose and side effects.

resultsRespiratory disorders pose a major threat to the morbidity and mortality to public health globally. Pulmonary delivery can be achieved through various drug delivery devices such as nebulizers, dry powder inhalers, and metered dose inhalers. Among them, metered dose inhalers are the most interesting and first choice of clinician over others. This review focused on nanotechnology based pulmonary drug delivery using metered dose inhalers. This report focused on delivery of various types of therapeutics using nanocarriers such as polymeric nanoparticles and micelles, dendrimers, lipid nanocarriers such as liposomes, solid lipid nanostructures and nanostructured lipid carriers, and other using metered dose inhalers discussed comprehensively. This report provides insight about the effect of parameters of MDI such as co-solvent, propellants, actuators shape, nozzle diameters, and jet lengths, and respiratory flow rate, and particle size of co-suspension of drug on aerodynamics and lung deposition of formulation. This review also provided the insight about various metered dose inhalers market scenario and digital metered dose inhalers.

conclusionThis report concluded the clinical potential of metered dose inhalers, summary of current progress and future perspectives towards the smart digital metered dose inhalers development.

Indexed as

Metered Dose InhalersPulmonary Disease, Chronic ObstructiveAdministration, InhalationDrug Delivery SystemsDry Powder InhalersHumansLipidsLungNanotechnologyNebulizers and VaporizersLipidscancerdrug deliverymetered dose inhalersnanocarrierspulmonary delivery

Identifiers

PMID35552983
PMCPMC9097569
OpenAlexW4280521838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.